CO2017006870A2 - Métodos de producción de polipéptidos de hormona de crecimiento modificada por ctp - Google Patents
Métodos de producción de polipéptidos de hormona de crecimiento modificada por ctpInfo
- Publication number
- CO2017006870A2 CO2017006870A2 CONC2017/0006870A CO2017006870A CO2017006870A2 CO 2017006870 A2 CO2017006870 A2 CO 2017006870A2 CO 2017006870 A CO2017006870 A CO 2017006870A CO 2017006870 A2 CO2017006870 A2 CO 2017006870A2
- Authority
- CO
- Colombia
- Prior art keywords
- ctp
- hgh
- modified
- growth hormone
- polypeptides
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title 1
- 108010051696 Growth Hormone Proteins 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 10
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 10
- 239000000854 Human Growth Hormone Substances 0.000 abstract 7
- 102000011022 Chorionic Gonadotropin Human genes 0.000 abstract 5
- 108010062540 Chorionic Gonadotropin Proteins 0.000 abstract 5
- 229940015047 chorionic gonadotropin Drugs 0.000 abstract 4
- 238000004113 cell culture Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 abstract 1
- 230000004989 O-glycosylation Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
- G06Q10/063—Operations research, analysis or management
- G06Q10/0633—Workflow analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
- G06Q10/063—Operations research, analysis or management
- G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
- G06Q10/063—Operations research, analysis or management
- G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
- G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0201—Market modelling; Market analysis; Collecting market data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Business, Economics & Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Human Resources & Organizations (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Strategic Management (AREA)
- Biotechnology (AREA)
- Entrepreneurship & Innovation (AREA)
- Economics (AREA)
- Development Economics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Educational Administration (AREA)
- Marketing (AREA)
- General Business, Economics & Management (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Game Theory and Decision Science (AREA)
- Reproductive Health (AREA)
- Tourism & Hospitality (AREA)
- Finance (AREA)
- Accounting & Taxation (AREA)
- Operations Research (AREA)
Abstract
En la presente solicitud se describen polipéptidos de la hormona de crecimiento humano (hGH) modificada con un péptido del extremo terminal carboxi de gonadotropina coriónica humana (CTP) que consiste en dos CTPs unidas al terminal carboxi de la hGH y una CTP unida al terminal amino de la hGH en donde el polipéptido de hGH modificada con CTP comprende glicosilación entre los sitios de glicosilación 13 y 18 unidos a O y métodos de obtención de los mismos. Métodos para producir el polipéptido hGH recombinante modificado con CTP incluyen realizar secuencialmente los pasos estableciendo un cultivo celular de células mamíferas que expresen y secreten polipeptidos hGH modificados con CTP glicosilados, los pasos incluyen expandir el cultivo celular que expresa hGH modificado con CTP, cosechar la solución que contienen hGH modificada con CTP secretada, y purificar la hGH modificada con CTP a 90-100% de pureza.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462090104P | 2014-12-10 | 2014-12-10 | |
US201462090116P | 2014-12-10 | 2014-12-10 | |
US201462090124P | 2014-12-10 | 2014-12-10 | |
PCT/IL2015/051196 WO2016092549A1 (en) | 2014-12-10 | 2015-12-10 | Methods of producing long acting ctp-modified growth hormone polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2017006870A2 true CO2017006870A2 (es) | 2018-01-05 |
Family
ID=56106835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2017/0006870A CO2017006870A2 (es) | 2014-12-10 | 2017-07-10 | Métodos de producción de polipéptidos de hormona de crecimiento modificada por ctp |
Country Status (22)
Country | Link |
---|---|
US (3) | US20160168588A1 (es) |
EP (4) | EP4212546A1 (es) |
KR (3) | KR20200118505A (es) |
CN (1) | CN107438623B (es) |
AU (2) | AU2015358890B2 (es) |
CO (1) | CO2017006870A2 (es) |
EA (1) | EA201791275A1 (es) |
ES (1) | ES2943359T3 (es) |
HK (2) | HK1243444A1 (es) |
HR (1) | HRP20230405T8 (es) |
IL (2) | IL252778B (es) |
MX (2) | MX2017007635A (es) |
NZ (1) | NZ733113A (es) |
PE (1) | PE20171380A1 (es) |
PH (1) | PH12017501089A1 (es) |
PL (1) | PL3230309T3 (es) |
RU (2) | RU2021103436A (es) |
SG (1) | SG11201704706RA (es) |
SI (1) | SI3230309T1 (es) |
TW (2) | TW202231657A (es) |
WO (2) | WO2016092549A1 (es) |
ZA (1) | ZA201704595B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
EP4212546A1 (en) | 2014-12-10 | 2023-07-19 | OPKO Biologics Ltd. | Methods of producing long acting ctp-modified polypeptides |
IL301728A (en) | 2015-06-19 | 2023-05-01 | Opko Biologics Ltd | Long-term coagulation factors and methods for their preparation |
BR112019000610A2 (pt) * | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
RU2652884C1 (ru) * | 2016-11-25 | 2018-05-03 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина |
US20200262887A1 (en) * | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
WO2021005604A1 (en) * | 2019-07-11 | 2021-01-14 | Opko Biologics Ltd. | Long-acting igf-1 or igf-1 variants and methods of producing same |
WO2022197963A1 (en) * | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Long-acting growth hormone compositions |
JP2022145646A (ja) * | 2021-03-19 | 2022-10-04 | ファイザー・インコーポレイテッド | 長時間作用型成長ホルモンポリペプチドを投与する方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
EP0264166B1 (en) | 1986-04-09 | 1996-08-21 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
ATE110571T1 (de) | 1988-05-06 | 1994-09-15 | Toray Industries | Stabile interferon-beta-zusammensetzung. |
EP0461200B1 (en) | 1989-02-21 | 1997-01-22 | Washington University | Modified forms of reproductive hormones |
ATE109507T1 (de) * | 1989-04-28 | 1994-08-15 | Miles Inc | Grossfermenter-inokulation mit gefrorenen zellen. |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
ES2141229T3 (es) * | 1993-04-20 | 2000-03-16 | Univ Washington | Productos farmaceuticos de proteinas y peptidos modificados. |
US5898030A (en) * | 1994-06-17 | 1999-04-27 | Applied Research Systems Ars Holding N.V | hGH containing pharmaceutical compositions |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
CN1847265A (zh) * | 2005-04-15 | 2006-10-18 | 上海市计划生育科学研究所 | 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途 |
US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8048849B2 (en) * | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8759292B2 (en) * | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) * | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR20130142128A (ko) * | 2010-10-11 | 2013-12-27 | 애브비 인코포레이티드 | 단백질의 정제 방법 |
MY172539A (en) | 2012-02-14 | 2019-11-30 | Opko Biologics Ltd | Long-acting coagulation factors and methods of producing same |
WO2013152351A2 (en) * | 2012-04-06 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Fusion polypeptides and methods of use thereof |
SG11201406671RA (en) * | 2012-04-19 | 2014-11-27 | Opko Biolog Ltd | Long-acting oxyntomodulin variants and methods of producing same |
EP2682168A1 (en) * | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
MY172997A (en) * | 2012-11-20 | 2019-12-18 | Opko Biologics Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
WO2014166836A1 (en) * | 2013-04-05 | 2014-10-16 | Novo Nordisk A/S | Growth hormone compound formulation |
EP4212546A1 (en) | 2014-12-10 | 2023-07-19 | OPKO Biologics Ltd. | Methods of producing long acting ctp-modified polypeptides |
IL301728A (en) * | 2015-06-19 | 2023-05-01 | Opko Biologics Ltd | Long-term coagulation factors and methods for their preparation |
-
2015
- 2015-12-10 EP EP22209083.9A patent/EP4212546A1/en active Pending
- 2015-12-10 US US14/965,079 patent/US20160168588A1/en not_active Abandoned
- 2015-12-10 EP EP15828386.1A patent/EP3230309B1/en active Active
- 2015-12-10 AU AU2015358890A patent/AU2015358890B2/en active Active
- 2015-12-10 MX MX2017007635A patent/MX2017007635A/es unknown
- 2015-12-10 ES ES15828386T patent/ES2943359T3/es active Active
- 2015-12-10 RU RU2021103436A patent/RU2021103436A/ru unknown
- 2015-12-10 SG SG11201704706RA patent/SG11201704706RA/en unknown
- 2015-12-10 PE PE2017000987A patent/PE20171380A1/es unknown
- 2015-12-10 HR HRP20230405TT patent/HRP20230405T8/hr unknown
- 2015-12-10 MX MX2017007634A patent/MX2017007634A/es unknown
- 2015-12-10 KR KR1020207028408A patent/KR20200118505A/ko not_active Application Discontinuation
- 2015-12-10 CN CN201580073554.7A patent/CN107438623B/zh active Active
- 2015-12-10 KR KR1020177018890A patent/KR102164352B1/ko active IP Right Grant
- 2015-12-10 EP EP15867141.2A patent/EP3240564A4/en not_active Withdrawn
- 2015-12-10 KR KR1020227010215A patent/KR102527180B1/ko active IP Right Grant
- 2015-12-10 EA EA201791275A patent/EA201791275A1/ru unknown
- 2015-12-10 TW TW110139563A patent/TW202231657A/zh unknown
- 2015-12-10 NZ NZ733113A patent/NZ733113A/en unknown
- 2015-12-10 WO PCT/IL2015/051196 patent/WO2016092549A1/en active Application Filing
- 2015-12-10 WO PCT/IL2015/051197 patent/WO2016092550A2/en active Application Filing
- 2015-12-10 RU RU2017123789A patent/RU2743295C2/ru active
- 2015-12-10 PL PL15828386.1T patent/PL3230309T3/pl unknown
- 2015-12-10 US US15/533,910 patent/US20180111974A1/en active Pending
- 2015-12-10 EP EP23164376.8A patent/EP4253407A3/en active Pending
- 2015-12-10 TW TW104141620A patent/TWI746427B/zh active
- 2015-12-10 SI SI201531936T patent/SI3230309T1/sl unknown
-
2017
- 2017-06-08 IL IL252778A patent/IL252778B/en unknown
- 2017-06-08 IL IL252788A patent/IL252788B/en unknown
- 2017-06-09 PH PH12017501089A patent/PH12017501089A1/en unknown
- 2017-07-07 ZA ZA2017/04595A patent/ZA201704595B/en unknown
- 2017-07-10 CO CONC2017/0006870A patent/CO2017006870A2/es unknown
-
2018
- 2018-03-02 HK HK18103050.1A patent/HK1243444A1/zh unknown
- 2018-05-07 HK HK18105854.4A patent/HK1246322A1/zh unknown
-
2019
- 2019-05-22 AU AU2019203609A patent/AU2019203609B2/en active Active
-
2021
- 2021-02-01 US US17/164,438 patent/US20210371487A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017006870A2 (es) | Métodos de producción de polipéptidos de hormona de crecimiento modificada por ctp | |
AR095615A1 (es) | Purificación de anticuerpos y monitoreo de pureza | |
WO2015120287A3 (en) | Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids | |
TN2015000416A1 (en) | Interleukin-2 muteins for the expansion of t-regulatory cells | |
MX2016004564A (es) | Cultivo celular metabolicamente optimizado. | |
EP3597664A3 (en) | Temperature shift for high yield expression of polypeptides in yeast and other transformed cells | |
BR112017011662A2 (pt) | parceiros de fusão para a produção de peptídeo | |
PE20142405A1 (es) | Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas | |
ES2627117T3 (es) | Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes | |
AR083114A1 (es) | Produccion de anticuerpos de fucosa baja en celulas de rata h4-ii-e | |
MX2016007207A (es) | Metodos mejorados para la produccion de polipeptidos recombinantes. | |
BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
EP3874023A4 (en) | ENHANCED PERFUSION CELL CULTURE PROCEDURE WITH CONTINUOUS HARVESTING AND WITHOUT CELL BLEEDING | |
MX2016003705A (es) | Formulacion de un conjugado de hormona del crecimiento humana de accion prolongada. | |
EP4332231A3 (en) | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest | |
EA201791059A1 (ru) | Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений | |
EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
EP3448884C0 (en) | MANIPULATED MAMMALIAN CELLS FOR THE PRODUCTION OF RECOMBINANT PROTEINS | |
CO2018006654A2 (es) | Proceso de producción de una gonadotrofina coriónica equina recombinante (recg), composición veterinaria y uso | |
AR095117A1 (es) | TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO | |
AR100273A1 (es) | Proceso de preparación de un material compuesto de carbono con vistas a su uso para la fabricación de bloques de carbono | |
MY184625A (en) | Methods of producing long acting ctp-modified growth hormone polypeptides | |
ES2523016A1 (es) | Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes | |
BR112016012325A2 (pt) | métodos para amidação c-terminal in vivo de um polipeptídeo e para a produção recombinante de um polipeptídeo e uso de uma peptidilglicina | |
AR117743A1 (es) | MÉTODO DE OBTENCIÓN DE UNA LÍNEA CELULAR DE MAMÍFERO QUE EXPRESA UNA HORMONA GONADOTROFINA CORIÓNICA EQUINA RECOMBINANTE (reCG), LÍNEA CELULAR QUE EXPRESA reCG, MÉTODO DE PRODUCCIÓN A ESCALA DE reCG, reCG, FORMULACIONES QUE LA CONTIENEN, ÁCIDOS NUCLEICOS QUE CODIFICAN PARA reCG Y USOS |